Evaluation of the Safety and Performance of Glycobone in Sinus Lift

NCT ID: NCT05377710

Last Updated: 2022-05-17

Basic Information

• Recruitment Status: UNKNOWN
• Clinical Phase: NA
• Total Enrollment: 40 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2022-05-16
• Study Completion Date: 2022-05-16

Brief Summary

Multicentre, interventional, longitudinal, open-label study conducted in France, evaluating the clinical performance and safety of Glycobone® as a bone filling material in the context of a lateral approach sinus lift on 40 patients with dental implant placement. Implant placement took place 6 months after bone filling.

Detailed Description

A multicentre, interventional, longitudinal, open-label, prospective, pilot exploratory study of first-in-man administration in France, evaluating the clinical performance, safety and bone filling properties of Glycobone® during a lateral sinus lift procedure with deferred implant placement.

The study will follow a panel of 40 patients for 9 months in three consecutive stages:

Stage 1: Inclusion of a group of up to 5 patients Stage 2: If safety validation in stage 1 is confirmed: Inclusion of a group of 15 additional patients (maximum) Step 3: If safety validation in step 2 is confirmed: Inclusion of a group of 20 additional patients.

Conditions

Sinus Elevation; Bone Substitute

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Glycobone

Patients will be implanted at T0 with Glycobone

Group Type: EXPERIMENTAL

sinus lift with lateral approach

Intervention Type: PROCEDURE

Maxillary sinus floor augmentation or sinus lift is a surgical procedure, which provides a solution to the problem of sinus bone loss (too thin), and thus increases the thickness of the bone for immediate or subsequent implant placement in the premolars and molars (4). It consists of the elevation of the sinus mucosa that lines the maxillary sinus. The space thus freed will be filled with a bone filling material

Interventions

sinus lift with lateral approach

Maxillary sinus floor augmentation or sinus lift is a surgical procedure, which provides a solution to the problem of sinus bone loss (too thin), and thus increases the thickness of the bone for immediate or subsequent implant placement in the premolars and molars (4). It consists of the elevation of the sinus mucosa that lines the maxillary sinus. The space thus freed will be filled with a bone filling material

Intervention Type: PROCEDURE

Other Intervention Names

sinus elevation

Eligibility Criteria

Inclusion Criteria

• 1. Adult patient, male or female, aged 18-84 years at the time of signing the consent form

2. Patient who has been informed and has signed consent prior to any procedure related to the investigation 3. Patient requiring a dental implant procedure:

• Implant project associated with at least one lateral approach sinus lift due to sub-sinus bone height < 5 mm, without full bridge
• Associated with a bone filling
• With implant placement deferred to approximately 6 months within the limit of a maximum of 3 implants in the framework of the investigation 4. Availability of a cone beam with radiological guide less than 3 months old 5. Patient covered by a health insurance plan.

Exclusion Criteria

1. 3 months or less old tooth extraction (≤ 3 months)

2. Sinus lift project requiring placement of all contralateral implants at the same time (i.e. 2 sinus lift projects associated with a full bridge)

3. Contralateral sinus lift of the site to be included performed within 3 months prior to inclusion

4. 4. Patient's general condition does not allow the investigator to perform the investigative procedures

5. Pregnant or breastfeeding patient at the time of the sinus lift and filling procedure (D0)

6. Patient with a concomitant ENT infection that may interfere with the investigative procedures

7. Patient with an uncontrolled chronic condition that may interfere with investigative procedures

8. Patient on VKA with INR >4, biphosphonates, denosumab or having been treated with radiotherapy in the study area

9. Patient unable to receive any type of analgesic during the investigation

10. Patient allergic to any of the components of Glycobone®.

11. Patient participating or having participated in another drug or medical device clinical trial within 30 days prior to inclusion in this study

12. Patient considered by the investigator to be non-compliant with study procedures

13. Patient deprived of liberty by court or administrative order or under legal protection (e.g. guardianship)

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 84 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: Yes

Sponsors

SILTISS

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Jean PAUFIQUE

Role: STUDY_DIRECTOR

SILTISS

Sylvain CATROS

Role: PRINCIPAL_INVESTIGATOR

University Hospital, Bordeaux

Central Contacts

Sandrine AUGET

Role: CONTACT

s.auget@siltiss.fr

+33 (0)5 55 84 58 40

Didier LETOURNEUR

Role: CONTACT

didier.letourneur@siltiss.fr

+33 (0)5 55 84 58 40

Other Identifiers

2020-A02457-32

Identifier Type: -

Identifier Source: org_study_id